Ille, Alexander M.
Markosian, Christopher
Burley, Stephen K.
Mathews, Michael B.
Pasqualini, Renata
Arap, Wadih
Funding for this research was provided by:
National Science Foundation (DBI-1832184)
U.S. Department of Energy (DE-SC0019749)
National Institutes of Health (R01GM133198, R01CA226537)
Levy-Longenbaugh Donor-Advised Fund
Rutgers Cancer Institute (P30CA072720)
Article History
Received: 26 March 2024
Accepted: 30 July 2024
First Online: 21 August 2024
Competing interests
: A.M.I. is a founder and partner of North Horizon, which is engaged in the development of artificial intelligence-based software. C.M. declares no competing interests. S.K.B. declares no competing interests. M.B.M. declares no competing interests. R.P. is a founder and equity shareholder of PhageNova Bio. R.P. is Chief Scientific Officer and a paid consultant of PhageNova Bio. R.P. is a founder and equity shareholder of MBrace Therapeutics. R.P. serves as a paid consultant for MBrace Therapeutics. R.P. has Sponsored Research Agreements (SRAs) in place with PhageNova Bio and with MBrace Therapeutics. These arrangements are managed in accordance with the established institutional conflict-of-interest policies of Rutgers, The State University of New Jersey. This study falls outside of the scope of these SRAs. W.A. is a founder and equity shareholder of PhageNova Bio. W.A. is a founder and equity shareholder of MBrace Therapeutics. W.A. serves as a paid consultant for MBrace Therapeutics. W.A. has Sponsored Research Agreements (SRAs) in place with PhageNova Bio and with MBrace Therapeutics. These arrangements are managed in accordance with the established institutional conflict-of-interest policies of Rutgers, The State University of New Jersey. This study falls outside of the scope of these SRAs.